Curis Announces Presentation of Preclinical Data From Small Molecule PD-L1/VISTA and IRAK4 Programs at the AACR-NCI-EORTC International Conference

On November 2, 2015 Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, reported that its collaborator, Aurigene Discovery Technologies Limited, will present data from two programs at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) to be held from November 5 – 9, 2015, in Boston, MA (Press release, Curis, NOV 2, 2015, View Source [SID:1234507871]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Curis’ collaborator, Aurigene will present data from CA-170 (previously AUPM-170), a first-in-class oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA) as well as from the interleukin-1 receptor association kinase4 (IRAK4) inhibitor program. Curis recently exercised options to license both these programs under a collaboration agreement with Aurigene established earlier this year.

Additional information on the presentations can be found below and abstracts can be accessed at www.aacr.org.

Poster Presentations

Date/Time: Friday, Nov. 6, 2015, 12:15 PM – 3:15 PM
Session Title: Immune Modulators
Presentation Title: First-in-class orally available immune checkpoint antagonists for cancer therapy
Location: Session A, Hall C-D
Abstract Number: A96

Date/Time: Sunday, Nov. 8, 2015, 12:30 PM – 3:30 PM
Session Title: Therapeutic Agents: Small Molecule Kinase Inhibitors
Presentation Title: Efficacy of novel IRAK4 inhibitors in ABC-DLBCL and AML models
Location: Session C, Hall C-D
Abstract Number: C191